The Claim
In children and adolescents with functional abdominal pain or irritable bowel syndrome, open-label placebo does not significantly improve global self-reported improvement compared to a no-treatment control period, despite reductions in pain and medication use.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In children and adolescents with functional abdominal pain or irritable bowel syndrome, taking a placebo pill they know is inactive does not lead to a significant improvement in their overall self-reported condition compared to no treatment, even though pain and medication use decrease.
See the scientific wording
In children and adolescents with functional abdominal pain or irritable bowel syndrome, open-label placebo does not significantly improve global self-reported improvement compared to a no-treatment control period, despite reductions in pain and medication use, suggesting that subjective global assessment may be less sensitive than objective or daily symptom measures.
When children and teens with stomach pain take a sugar pill they know is inert, their pain decreases and they use less medicine, but many still don’t feel they are 'much better' overall because their brain doesn’t update its overall sense of well-being even when daily symptoms improve.
What the research says
1 studyKids with stomach pain felt less pain and took fewer pills when told they were taking a sugar pill, but only about half said they felt 'much better' overall — meaning asking them if they feel better doesn’t always catch the real improvement.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.